SPA - ARCA Bio updates on mid-stage rNAPc2 study in COVID-19 shares down 9%

Gilnature/iStock via Getty Images ARCA biopharma ([[ABIO]] -9.2%) provides an update on ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19. ARCA has received approval from regulatory authorities in Argentina and Brazil to enroll patients in ASPEN-COVID-19. The Company anticipates enrolling the first South American patients in this month. Trial target enrollment is being increased from 100 to 160 patients in order to maximize the sample size for determining any differences in two rNAPc2 dose regimens, to minimize variance in the standard of care heparin control arm, and to account for evolving changes in the clinical course of COVID-19. To date, 77 patients have been enrolled. The Company also updated its guidance and now anticipates topline data from Phase 2b trial in Q4 2021. The primary is the change in D-dimer level from baseline to Day 8 relative to standard of care heparin. Other

For further details see:

ARCA Bio updates on mid-stage rNAPc2 study in COVID-19, shares down 9%